Halozyme Therapeutics (NASDAQ:HALO) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday.

Several other equities analysts have also recently commented on HALO. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Wednesday, July 11th. BMO Capital Markets boosted their price objective on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the company a “market perform” rating in a research note on Wednesday, August 8th. Cantor Fitzgerald initiated coverage on shares of Halozyme Therapeutics in a research note on Wednesday, August 22nd. They set an “overweight” rating and a $27.00 price objective for the company. Finally, Piper Jaffray Companies initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday. They set a “hold” rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $20.78.

NASDAQ HALO opened at $16.36 on Friday. Halozyme Therapeutics has a 12-month low of $16.06 and a 12-month high of $21.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.43 and a current ratio of 3.49. The company has a market capitalization of $2.54 billion, a PE ratio of 36.36 and a beta of 1.81.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. The company had revenue of $35.20 million during the quarter, compared to analysts’ expectations of $31.49 million. Halozyme Therapeutics had a net margin of 23.88% and a return on equity of 38.10%. Research analysts predict that Halozyme Therapeutics will post -0.8 earnings per share for the current fiscal year.

In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 103,900 shares of the business’s stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $17.32, for a total value of $1,799,548.00. Following the completion of the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at approximately $61,700,560.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Randal J. Kirk sold 161,246 shares of the business’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $17.15, for a total transaction of $2,765,368.90. Following the completion of the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at approximately $61,094,954.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,920,195 shares of company stock valued at $68,779,363. 16.80% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Element Capital Management LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth approximately $198,000. Raymond James & Associates bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $222,000. Amalgamated Bank lifted its holdings in shares of Halozyme Therapeutics by 19.3% in the 2nd quarter. Amalgamated Bank now owns 19,053 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 3,077 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $326,000. Finally, Xact Kapitalforvaltning AB lifted its holdings in shares of Halozyme Therapeutics by 26.1% in the 1st quarter. Xact Kapitalforvaltning AB now owns 18,369 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 3,800 shares during the last quarter. 83.88% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Story: What is a stock buyback?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.